← All trials
NCT05978206
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 10, 2023
- Primary completion
- Jun 12, 2026
- Completion date
- Oct 30, 2026
- First posted
- Aug 7, 2023
- Last posted
- Nov 14, 2023
- Enrollment
- 168
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of PolandLead sponsor
- Government of PolandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.